{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T17:27:38Z","timestamp":1790270858342,"version":"4.1.0"},"reference-count":101,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Liver Disease"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.cld.2019.04.005","type":"journal-article","created":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T02:17:42Z","timestamp":1558664262000},"page":"557-572","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":56,"title":["HBV\/HDV Coinfection"],"prefix":"10.1016","volume":"23","author":[{"given":"Christopher","family":"Koh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben L.","family":"Da","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey S.","family":"Glenn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cld.2019.04.005_bib1","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1136\/gut.18.12.997","article-title":"Immunofluorescence detection of new antigen-antibody system (delta\/anti-delta) associated to hepatitis B virus in liver and in serum of HBsAg carriers","volume":"18","author":"Rizzetto","year":"1977","journal-title":"Gut"},{"key":"10.1016\/j.cld.2019.04.005_bib2","first-page":"1","article-title":"Structure and replication of hepatitis delta virus RNA","volume":"307","author":"Taylor","year":"2006","journal-title":"Curr Top Microbiol Immunol"},{"key":"10.1016\/j.cld.2019.04.005_bib3","doi-asserted-by":"crossref","first-page":"437","DOI":"10.7326\/0003-4819-98-4-437","article-title":"Chronic hepatitis in carriers of hepatitis B surface antigen, with intrahepatic expression of the delta antigen. An active and progressive disease unresponsive to immunosuppressive treatment","volume":"98","author":"Rizzetto","year":"1983","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cld.2019.04.005_bib4","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1111\/j.1365-2893.2010.01353.x","article-title":"Natural history and treatment of chronic delta hepatitis","volume":"17","author":"Yurdaydin","year":"2010","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.cld.2019.04.005_bib5","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.jhep.2015.04.025","article-title":"Delta hepatitis within the Veterans Affairs medical system in the United States: prevalence, risk factors, and outcomes","volume":"63","author":"Kushner","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2019.04.005_bib6","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1002\/hep.1840070627","article-title":"The epidemiology and clinical outcome of hepatitis D virus (delta) infection in Jordan","volume":"7","author":"Toukan","year":"1987","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2019.04.005_bib7","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1053\/j.gastro.2009.01.052","article-title":"A\u00a028-year study of the course of hepatitis Delta infection: a risk factor for cirrhosis and hepatocellular carcinoma","volume":"136","author":"Romeo","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2019.04.005_bib8","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/j.1440-1746.1993.tb01543.x","article-title":"Risk of liver cirrhosis and hepatocellular carcinoma in subjects with hepatitis B and delta virus infection: a study from Kure, Japan","volume":"8","author":"Tamura","year":"1993","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2019.04.005_bib9","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1136\/gut.46.3.420","article-title":"Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. The European Concerted Action on Viral Hepatitis (Eurohep)","volume":"46","author":"Fattovich","year":"2000","journal-title":"Gut"},{"key":"10.1016\/j.cld.2019.04.005_bib10","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1093\/jnci\/djs168","article-title":"A\u00a0population-based study of hepatitis D virus as potential risk factor for hepatocellular carcinoma","volume":"104","author":"Ji","year":"2012","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.cld.2019.04.005_bib11","doi-asserted-by":"crossref","first-page":"777","DOI":"10.4254\/wjh.v7.i5.777","article-title":"Hepatitis D and hepatocellular carcinoma","volume":"7","author":"Abbas","year":"2015","journal-title":"World J Hepatol"},{"key":"10.1016\/j.cld.2019.04.005_bib12","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.jhep.2016.10.007","article-title":"Hepatitis delta-associated mortality in HIV\/HBV-coinfected patients","volume":"66","author":"Beguelin","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2019.04.005_bib13","article-title":"Prevalence and burden of hepatitis D virus infection in the global population: a systematic review and meta-analysis","author":"Chen","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.cld.2019.04.005_bib14","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s11096-005-1319-7","article-title":"Side effects of interferon-alpha therapy","volume":"27","author":"Sleijfer","year":"2005","journal-title":"Pharm World Sci"},{"key":"10.1016\/j.cld.2019.04.005_bib15","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2019.04.005_bib16","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection","volume":"67","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2019.04.005_bib17","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1002\/hep.28876","article-title":"Antiviral treatment and liver-related complications in hepatitis delta","volume":"65","author":"Wranke","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2019.04.005_bib18","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1053\/j.gastro.2004.03.017","article-title":"Long-term benefit of interferon alpha therapy of chronic hepatitis D: regression of advanced hepatic fibrosis","volume":"126","author":"Farci","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2019.04.005_bib19","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1093\/infdis\/jix656","article-title":"Interferon treatment duration in patients with chronic delta hepatitis and its effect on the natural course of the disease","volume":"217","author":"Yurdaydin","year":"2018","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.cld.2019.04.005_bib20","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1177\/135965350501000603","article-title":"Two-year interferon therapy with or without ribavirin in chronic delta hepatitis","volume":"10","author":"Gunsar","year":"2005","journal-title":"Antivir Ther"},{"key":"10.1016\/j.cld.2019.04.005_bib21","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/hep.21296","article-title":"Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta","volume":"44","author":"Niro","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2019.04.005_bib22","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/j.1365-2893.2007.00936.x","article-title":"Treatment of chronic delta hepatitis with lamivudine vs lamivudine\u00a0+ interferon vs interferon","volume":"15","author":"Yurdaydin","year":"2008","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.cld.2019.04.005_bib23","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1002\/hep.510300217","article-title":"Lamivudine for chronic delta hepatitis","volume":"30","author":"Lau","year":"1999","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2019.04.005_bib24","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/S0168-8278(02)00162-9","article-title":"Famciclovir treatment of chronic delta hepatitis","volume":"37","author":"Yurdaydin","year":"2002","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2019.04.005_bib25","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/S0168-8278(14)60006-4","article-title":"Prolonged therapy of hepatitis delta for 96\u00a0weeks with pegylated-interferon-2a plus tenofovir or placebo does not prevent HDV RNA relapse after treatment: the HIDIT-2 study","volume":"60","author":"Wedemeyer","year":"2014","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2019.04.005_bib26","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa0912696","article-title":"Peginterferon plus adefovir versus either drug alone for hepatitis delta","volume":"364","author":"Wedemeyer","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cld.2019.04.005_bib27","first-page":"113","article-title":"The role of the HBV envelope proteins in the HDV replication cycle","volume":"307","author":"Sureau","year":"2006","journal-title":"Curr Top Microbiol Immunol"},{"key":"10.1016\/j.cld.2019.04.005_bib28","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1128\/jvi.58.3.945-950.1986","article-title":"Hepatitis delta virus: protein composition of delta antigen and its hepatitis B virus-derived envelope","volume":"58","author":"Bonino","year":"1986","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.cld.2019.04.005_bib29","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1093\/infdis\/141.5.590","article-title":"Transmission of the hepatitis B virus-associated delta antigen to chimpanzees","volume":"141","author":"Rizzetto","year":"1980","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.cld.2019.04.005_bib30","doi-asserted-by":"crossref","first-page":"4880","DOI":"10.1128\/jvi.69.8.4880-4887.1995","article-title":"Transgenic mice support replication of hepatitis delta virus RNA in multiple tissues, particularly in skeletal muscle","volume":"69","author":"Polo","year":"1995","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.cld.2019.04.005_bib31","doi-asserted-by":"crossref","first-page":"S102","DOI":"10.1016\/j.jhep.2016.02.013","article-title":"The hepatitis delta virus: replication and pathogenesis","volume":"64","author":"Sureau","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2019.04.005_bib32","doi-asserted-by":"crossref","first-page":"9786","DOI":"10.1128\/JVI.79.15.9786-9798.2005","article-title":"Mapping of the hepatitis B virus pre-S1 domain involved in receptor recognition","volume":"79","author":"Barrera","year":"2005","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.cld.2019.04.005_bib33","doi-asserted-by":"crossref","first-page":"e00049","DOI":"10.7554\/eLife.00049","article-title":"Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus","volume":"3","author":"Yan","year":"2012","journal-title":"Elife"},{"key":"10.1016\/j.cld.2019.04.005_bib34","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0140-6736(10)61931-9","article-title":"Hepatitis delta virus","volume":"378","author":"Hughes","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.cld.2019.04.005_bib35","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1128\/JVI.01758-07","article-title":"Transcription of hepatitis delta virus RNA by RNA polymerase II","volume":"82","author":"Chang","year":"2008","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.cld.2019.04.005_bib36","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1146\/annurev.bi.64.070195.001355","article-title":"The molecular biology of hepatitis delta virus","volume":"64","author":"Lai","year":"1995","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/j.cld.2019.04.005_bib37","first-page":"133","article-title":"Prenylation of HDAg and antiviral drug development","volume":"307","author":"Glenn","year":"2006","journal-title":"Curr Top Microbiol Immunol"},{"key":"10.1016\/j.cld.2019.04.005_bib38","first-page":"27","article-title":"Experimental hepatitis delta virus infection in the chimpanzee","volume":"234","author":"Purcell","year":"1987","journal-title":"Prog Clin Biol Res"},{"key":"10.1016\/j.cld.2019.04.005_bib39","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1128\/jvi.68.2.1052-1058.1994","article-title":"Expression of the hepatitis delta virus large and small antigens in transgenic mice","volume":"68","author":"Guilhot","year":"1994","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.cld.2019.04.005_bib40","doi-asserted-by":"crossref","first-page":"8120","DOI":"10.1128\/JVI.78.15.8120-8134.2004","article-title":"By inhibiting replication, the large hepatitis delta antigen can indirectly regulate amber\/W editing and its own expression","volume":"78","author":"Sato","year":"2004","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.cld.2019.04.005_bib41","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1128\/jvi.65.5.2357-2361.1991","article-title":"Trans-dominant inhibition of human hepatitis delta virus genome replication","volume":"65","author":"Glenn","year":"1991","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.cld.2019.04.005_bib42","doi-asserted-by":"crossref","first-page":"5066","DOI":"10.1128\/jvi.64.10.5066-5069.1990","article-title":"Role of two forms of hepatitis delta virus antigen: evidence for a mechanism of self-limiting genome replication","volume":"64","author":"Chao","year":"1990","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.cld.2019.04.005_bib43","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1002\/hep.1840130508","article-title":"Direct evidence for cytotoxicity associated with expression of hepatitis delta virus antigen","volume":"13","author":"Cole","year":"1991","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2019.04.005_bib44","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s11908-011-0233-5","article-title":"Current concept in the pathophysiology of hepatitis delta infection","volume":"14","author":"Niro","year":"2012","journal-title":"Curr Infect Dis Rep"},{"key":"10.1016\/j.cld.2019.04.005_bib45","first-page":"187","article-title":"Immunology of HDV infection","volume":"307","author":"Fiedler","year":"2006","journal-title":"Curr Top Microbiol Immunol"},{"key":"10.1016\/j.cld.2019.04.005_bib46","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/hep.28156","article-title":"AASLD guidelines for treatment of chronic hepatitis B","volume":"63","author":"Terrault","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2019.04.005_bib47","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1056\/NEJM199401133300202","article-title":"Treatment of chronic hepatitis D with interferon alfa-2a","volume":"330","author":"Farci","year":"1994","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cld.2019.04.005_bib48","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1002\/hep.21325","article-title":"Efficacy of peginterferon alpha-2b in chronic hepatitis delta: relevance of quantitative RT-PCR for follow-up","volume":"44","author":"Castelnau","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2019.04.005_bib49","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/apt.12788","article-title":"Long-term therapy of chronic delta hepatitis with peginterferon alfa","volume":"40","author":"Heller","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cld.2019.04.005_bib50","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1002\/hep.27357","article-title":"Understanding early serum hepatitis D virus and hepatitis B surface antigen kinetics during pegylated interferon-alpha therapy via mathematical modeling","volume":"60","author":"Guedj","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2019.04.005_bib51","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1016\/j.cgh.2015.05.029","article-title":"Association between level of hepatitis D virus RNA at week 24 of pegylated interferon therapy and outcome","volume":"13","author":"Keskin","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2019.04.005_bib52","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1128\/AAC.49.3.1135-1138.2005","article-title":"Alpha interferon and ribavirin combination therapy of chronic hepatitis D","volume":"49","author":"Kaymakoglu","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cld.2019.04.005_bib53","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1046\/j.1365-2893.2000.00254.x","article-title":"Lamivudine-high dose interferon combination therapy for chronic hepatitis B patients co-infected with the hepatitis D virus","volume":"7","author":"Wolters","year":"2000","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.cld.2019.04.005_bib54","first-page":"222A","article-title":"96\u00a0weeks of pegylated-interferon-alpha-2a plus tenofovir or placebo for the treatment of hepatitis delta: the HIDIT-2 study","volume":"58","author":"Wedemeyer","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2019.04.005_bib55","doi-asserted-by":"crossref","first-page":"e101002","DOI":"10.1371\/journal.pone.0101002","article-title":"Anti-HDV IgM as a marker of disease activity in hepatitis delta","volume":"9","author":"Wranke","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.cld.2019.04.005_bib56","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S1473-3099(18)30663-7","article-title":"Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial","volume":"19","author":"Wedemeyer","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cld.2019.04.005_bib57","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1002\/hep.1840140302","article-title":"Thymosin treatment of chronic hepatitis B: a placebo-controlled pilot trial","volume":"14","author":"Mutchnick","year":"1991","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2019.04.005_bib58","first-page":"774","article-title":"A\u00a0randomized controlled trial of thymosin-alpha1 versus interferon alfa treatment in patients with hepatitis B e antigen antibody--and hepatitis B virus DNA--positive chronic hepatitis B","volume":"24","author":"Andreone","year":"1996","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2019.04.005_bib59","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S1590-8658(02)80149-9","article-title":"Treatment of chronic hepatitis D with thymus-derived polypeptide thymic humoral factor-gamma 2: a pilot study","volume":"34","author":"Rosina","year":"2002","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.cld.2019.04.005_bib60","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1097\/00004836-199609000-00024","article-title":"A\u00a0pilot study of thymosin-alpha 1 therapy for chronic hepatitis D","volume":"23","author":"Zavaglia","year":"1996","journal-title":"J\u00a0Clin Gastroenterol"},{"key":"10.1016\/j.cld.2019.04.005_bib61","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.jhep.2015.12.018","article-title":"Peginterferon lambda for the treatment of HBeAg-positive chronic hepatitis B: a randomized phase 2b study (LIRA-B)","volume":"64","author":"Chan","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2019.04.005_bib62","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1186\/s40064-016-2920-z","article-title":"A\u00a0randomized, controlled study of peginterferon lambda-1a\/ribavirin\u00a0+\/- daclatasvir for hepatitis C virus genotype 2 or 3","volume":"5","author":"Foster","year":"2016","journal-title":"Springerplus"},{"key":"10.1016\/j.cld.2019.04.005_bib63","doi-asserted-by":"crossref","first-page":"4501","DOI":"10.1128\/JVI.80.9.4501-4509.2006","article-title":"Lambda interferon (IFN-lambda), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in\u00a0vivo","volume":"80","author":"Ank","year":"2006","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.cld.2019.04.005_bib64","doi-asserted-by":"crossref","first-page":"349575","DOI":"10.1155\/2011\/349575","article-title":"Interferon lambda: a new sword in cancer immunotherapy","volume":"2011","author":"Lasfar","year":"2011","journal-title":"Clin Dev Immunol"},{"key":"10.1016\/j.cld.2019.04.005_bib65","doi-asserted-by":"crossref","first-page":"3757","DOI":"10.1038\/s41598-017-03946-9","article-title":"Both interferon alpha and lambda can reduce all intrahepatic HDV infection markers in HBV\/HDV infected humanized mice","volume":"7","author":"Giersch","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.cld.2019.04.005_bib66","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.1016\/S0618-8278(19)30058-1","article-title":"End of study results from LIMT HDV study: 36% durable virologic response at 24\u00a0weeks post-treatment with pegylated interferon lambda monotherapy in patients with chronic hepatitis delta virus infection","volume":"70","author":"Etzion","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2019.04.005_bib67","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1002\/hep.21112","article-title":"Characterization of a hepatitis B and hepatitis delta virus receptor binding site","volume":"43","author":"Engelke","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2019.04.005_bib68","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1002\/hep.24758","article-title":"Humanized chimeric uPA mouse model for the study of hepatitis B and D virus interactions and preclinical drug evaluation","volume":"55","author":"Lutgehetmann","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2019.04.005_bib69","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1128\/JVI.79.3.1613-1622.2005","article-title":"Efficient inhibition of hepatitis B virus infection by acylated peptides derived from the large viral surface protein","volume":"79","author":"Gripon","year":"2005","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.cld.2019.04.005_bib70","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.jhep.2016.04.016","article-title":"Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: first results of a phase Ib\/IIa study","volume":"65","author":"Bogomolov","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2019.04.005_bib71","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/S0168-8278(18)30224-1","article-title":"Final results of a multicenter, open-label phase 2b clinical trial to assess safety and efficacy of Myrcludex B in combination with Tenofovir in patients with chronic HBV\/HDV co-infection","volume":"68","author":"Wedemeyer","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2019.04.005_bib72","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1136\/gutjnl-2017-314713","article-title":"Hepatitis delta virus persists during liver regeneration and is amplified through cell division both in\u00a0vitro and in\u00a0vivo","volume":"68","author":"Giersch","year":"2019","journal-title":"Gut"},{"key":"10.1016\/j.cld.2019.04.005_bib73","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/cpt.744","article-title":"The NTCP-inhibitor Myrcludex B: effects on bile acid disposition and tenofovir pharmacokinetics","volume":"103","author":"Blank","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.cld.2019.04.005_bib74","doi-asserted-by":"crossref","first-page":"267","DOI":"10.3851\/IMP3206","article-title":"Drug-drug interaction potential of the HBV and HDV entry inhibitor myrcludex B assessed in\u00a0vitro","volume":"23","author":"Blank","year":"2018","journal-title":"Antivir Ther"},{"key":"10.1016\/j.cld.2019.04.005_bib75","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1128\/AAC.00279-08","article-title":"Amphipathic DNA polymers exhibit antiherpetic activity in\u00a0vitro and in\u00a0vivo","volume":"52","author":"Bernstein","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cld.2019.04.005_bib76","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1177\/135965350701200810","article-title":"Amphipathic DNA polymers are candidate vaginal microbicides and block herpes simplex virus binding, entry and viral gene expression","volume":"12","author":"Guzman","year":"2007","journal-title":"Antivir Ther"},{"key":"10.1016\/j.cld.2019.04.005_bib77","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1053\/j.gastro.2009.04.048","article-title":"Amphipathic DNA polymers inhibit hepatitis C virus infection by blocking viral entry","volume":"137","author":"Matsumura","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2019.04.005_bib78","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1128\/AAC.50.4.1393-1401.2006","article-title":"Phosphorothioate oligonucleotides inhibit human immunodeficiency virus type 1 fusion by blocking gp41 core formation","volume":"50","author":"Vaillant","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cld.2019.04.005_bib79","doi-asserted-by":"crossref","first-page":"5291","DOI":"10.1128\/AAC.01003-13","article-title":"Nucleic acid polymers inhibit duck hepatitis B virus infection in\u00a0vitro","volume":"57","author":"Noordeen","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cld.2019.04.005_bib80","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01416-17","article-title":"Nucleic acid polymers are active against hepatitis delta virus infection in\u00a0vitro","volume":"92","author":"Beilstein","year":"2018","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.cld.2019.04.005_bib81","doi-asserted-by":"crossref","first-page":"e0140909","DOI":"10.1371\/journal.pone.0140909","article-title":"Therapeutic antiviral effect of the nucleic acid polymer REP 2055 against persistent duck hepatitis b virus infection","volume":"10","author":"Noordeen","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.cld.2019.04.005_bib82","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.antiviral.2019.02.009","article-title":"Inhibition of HBsAg secretion by nucleic acid polymers in HepG2.2.15cells","volume":"164","author":"Blanchet","year":"2019","journal-title":"Antiviral Res"},{"key":"10.1016\/j.cld.2019.04.005_bib83","first-page":"504A","article-title":"Interaction of nucleic acid polymers with the large and small forms of hepatitis delta antigen protein","volume":"66","author":"Shamur","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2019.04.005_bib84","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/S2468-1253(17)30288-1","article-title":"Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial","volume":"2","author":"Bazinet","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2019.04.005_bib85","doi-asserted-by":"crossref","first-page":"e0156667","DOI":"10.1371\/journal.pone.0156667","article-title":"Safety and efficacy of nucleic acid polymers in monotherapy and combined with immunotherapy in treatment-naive Bangladeshi patients with HBeAg+ chronic hepatitis B infection","volume":"11","author":"Al-Mahtab","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.cld.2019.04.005_bib86","doi-asserted-by":"crossref","first-page":"S509","DOI":"10.1016\/S0168-8278(18)31266-2","article-title":"Establishment of persistent functional remission of HBV and HDV infection following REP 2139 and pegylated interferon alpha 2a therapy in patients with chronic HBV\/HDV co-infection: 18\u00a0month follow-up results from the REP 301-LTF study","volume":"68","author":"Bazinet","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2019.04.005_bib87","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1081\/CLT-100100947","article-title":"Evidence of enhanced iron excretion during systemic phosphorothioate oligodeoxynucleotide treatment","volume":"38","author":"Mata","year":"2000","journal-title":"J\u00a0Toxicol Clin Toxicol"},{"key":"10.1016\/j.cld.2019.04.005_bib88","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/S2468-1253(17)30292-3","article-title":"Nucleic acid polymers: much-needed hope for hepatitis D?","volume":"2","author":"Alfaiate","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2019.04.005_bib89","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1136\/bmj.306.6870.107","article-title":"Fatal hepatic decompensation associated with interferon alfa. European concerted action on viral hepatitis (Eurohep)","volume":"306","author":"Janssen","year":"1993","journal-title":"BMJ"},{"key":"10.1016\/j.cld.2019.04.005_bib90","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1517\/14656560903066811","article-title":"Antiviral therapy in compensated and decompensated cirrhotic patients with chronic HCV infection","volume":"10","author":"Iacobellis","year":"2009","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.cld.2019.04.005_bib91","doi-asserted-by":"crossref","unstructured":"Bazinet M PV, Placinta G. Update on safety and efficacy in the REP 401 protocol: REP 2139-Mg or REP 2165-Mg used in combination with tenofovir disoproxil fumarate and pegylated Interferon alpha-2a in treatment naive Caucasian patients with chronic HBeAg negative HBV infection, In International Liver Congress. Amsterdam, Netherlands, April 19\u201323, 2017.","DOI":"10.1016\/S0168-8278(17)30821-8"},{"key":"10.1016\/j.cld.2019.04.005_bib92","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1517\/13543784.2012.688950","article-title":"Lonafarnib for cancer and progeria","volume":"21","author":"Wong","year":"2012","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.cld.2019.04.005_bib93","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1001\/jama.2018.3264","article-title":"Association of lonafarnib treatment vs no treatment with mortality rate in patients with Hutchinson-Gilford progeria syndrome","volume":"319","author":"Gordon","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.cld.2019.04.005_bib94","doi-asserted-by":"crossref","first-page":"10465","DOI":"10.1128\/JVI.76.20.10465-10472.2002","article-title":"A\u00a0prenylation inhibitor prevents production of infectious hepatitis delta virus particles","volume":"76","author":"Bordier","year":"2002","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.cld.2019.04.005_bib95","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/S1473-3099(15)00074-2","article-title":"Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial","volume":"15","author":"Koh","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cld.2019.04.005_bib96","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1002\/hep.29658","article-title":"Optimizing lonafarnib treatment for the management of chronic delta hepatitis: the LOWR HDV-1 study","volume":"67","author":"Yurdaydin","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2019.04.005_bib97","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1016\/S0168-8278(17)30327-6","article-title":"A\u00a0phase 2 dose-optimization study of lonafarnib with ritonavir for the treatment of chronic delta hepatitis-end of treatment results from the LOWR HDV-2 study","volume":"66","author":"Yurdaydin","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2019.04.005_bib98","doi-asserted-by":"crossref","first-page":"S101","DOI":"10.1016\/S0168-8278(17)30464-6","article-title":"A\u00a0phase 2 study exploring once daily dosing\u00a0of ritonavir boosted lonafarnib for the treatment of chronic delta hepatitis \u2013 end of study results from the LOWR HDV-3 study","volume":"66","author":"Koh","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2019.04.005_bib99","first-page":"121A","article-title":"A\u00a0phase 2 study of titrating-dose lonafarnib plus ritonavir in patients with chronic hepatitis D: interim results from the lonafarnib with ritonavir in HDV-4 (LOWR HDV-4) study","volume":"64","author":"Wedemeyer","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2019.04.005_bib100","first-page":"927A","article-title":"The prenylation inhibitor lonafarnib can induce post-treatment Alt flares with viral Cle","volume":"64","author":"Yurdaydin","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2019.04.005_bib101","doi-asserted-by":"crossref","first-page":"S259","DOI":"10.1016\/S0168-8278(17)30828-0","article-title":"The prenylation inhibitor lonafarnib can induce post-treatment viral clearance in patients with chronic delta hepatitis resulting in ALT normalization and regression of fibrosis","volume":"66","author":"Yurdaydin","year":"2017","journal-title":"J\u00a0Hepatol"}],"container-title":["Clinics in Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326119300182?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326119300182?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T17:56:24Z","timestamp":1761069384000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1089326119300182"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":101,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["S1089326119300182"],"URL":"https:\/\/doi.org\/10.1016\/j.cld.2019.04.005","relation":{},"ISSN":["1089-3261"],"issn-type":[{"value":"1089-3261","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"HBV\/HDV Coinfection","name":"articletitle","label":"Article Title"},{"value":"Clinics in Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cld.2019.04.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}